How big is the and japan tumor immunotherapy market?

Buyers of the report can access verified and reliable market forecasts including those for the overall size of the global Tumor Immunotherapy market in terms of revenue.On the whole the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Tumor Immunotherapy market.Market Analysis and Insights Global Tumor Immunotherapy MarketThe global Tumor Immunotherapy market size is projected to reach US XX million by 2027 from US XX million in 2020 at a CAGR of XX during 20212027.With industrystandard accuracy in analysis and high data integrity the report makes a brilliant attempt to unveil key opportunities available in the global Tumor Immunotherapy market to help players in achieving a strong market position.

BUY CHAPTERS

Tumor Immunotherapy Market Insights and Forecast to 2028

Code: QYRE-Auto-18E7950

Report

April 2022

Pages:129

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

Tumor Immunotherapy Market Outlook - 2028

The global Tumor Immunotherapy market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.

Fully considering the economic change by this health crisis, Tumor Infiltrating Lymphocyte (TIL) Treatment accounting for % of the Tumor Immunotherapy global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period.

While Biopharmaceutical Company segment is altered to an % CAGR throughout this forecast period.

Tumor Immunotherapy Market Size and Share

China Tumor Immunotherapy market size is valued at US$ million in 2021, while the North America and Europe Tumor Immunotherapy are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period.

As for the Europe Tumor Immunotherapy landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Tumor Immunotherapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Tumor Immunotherapy market in terms of revenue.

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Tumor Immunotherapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Tumor Immunotherapy market.

Tumor Immunotherapy market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Tumor Immunotherapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Segment By Type

Tumor Infiltrating Lymphocyte (TIL) Treatment
Engineered T Cell Receptor (TCR) Therapy
Chimeric Antigen Receptor (CAR) T Cell Therapy
Natural Killer (NK) Cell Therapy
Other

Segment By Application

Biopharmaceutical Company
Hospital
Universities And Other Scientific Research Institutions
Other

By Company

Roche
Merck
Novartis
Johnson & Johnson
GlaxoSmithKline
AbbVie
ELI Lilly
Amgen
AstraZeneca
Bristol-Mysers Squibb
Kite Pharma
Adaptimmune
Altor Bioscience Corporation
Cellectis
Juno Therapeutics
Takara Bio
Unum Therapeutics
Sunway
Junshi Bio
Cinda Bio
BeiGene

By Region

North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

1 Report Business Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Tumor Immunotherapy Market Size Growth Rate by Type, 2017 VS 2021 VS 2028

1.2.2 Tumor Infiltrating Lymphocyte (TIL) Treatment

1.2.3 Engineered T Cell Receptor (TCR) Therapy

1.2.4 Chimeric Antigen Receptor (CAR) T Cell Therapy

1.2.5 Natural Killer (NK) Cell Therapy

1.2.6 Other

1.3 Market by Application

1.3.1 Global Tumor Immunotherapy Market Size Growth Rate by Application, 2017 VS 2021 VS 2028

1.3.2 Biopharmaceutical Company

1.3.3 Hospital

1.3.4 Universities And Other Scientific Research Institutions

1.3.5 Other

1.4 Study Objectives

1.5 Years Considered

2 Global Growth Trends

2.1 Global Tumor Immunotherapy Market Perspective (2017-2028)

2.2 Tumor Immunotherapy Growth Trends by Region

2.2.1 Tumor Immunotherapy Market Size by Region: 2017 VS 2021 VS 2028

2.2.2 Tumor Immunotherapy Historic Market Size by Region (2017-2022)

2.2.3 Tumor Immunotherapy Forecasted Market Size by Region (2023-2028)

2.3 Tumor Immunotherapy Market Dynamics

2.3.1 Tumor Immunotherapy Industry Trends

2.3.2 Tumor Immunotherapy Market Drivers

2.3.3 Tumor Immunotherapy Market Challenges

2.3.4 Tumor Immunotherapy Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Tumor Immunotherapy Players by Revenue

3.1.1 Global Top Tumor Immunotherapy Players by Revenue (2017-2022)

3.1.2 Global Tumor Immunotherapy Revenue Market Share by Players (2017-2022)

3.2 Global Tumor Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Tumor Immunotherapy Revenue

3.4 Global Tumor Immunotherapy Market Concentration Ratio

3.4.1 Global Tumor Immunotherapy Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Tumor Immunotherapy Revenue in 2021

3.5 Tumor Immunotherapy Key Players Head office and Area Served

3.6 Key Players Tumor Immunotherapy Product Solution and Service

3.7 Date of Enter into Tumor Immunotherapy Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Tumor Immunotherapy Breakdown Data by Type

4.1 Global Tumor Immunotherapy Historic Market Size by Type (2017-2022)

4.2 Global Tumor Immunotherapy Forecasted Market Size by Type (2023-2028)

5 Tumor Immunotherapy Breakdown Data by Application

5.1 Global Tumor Immunotherapy Historic Market Size by Application (2017-2022)

5.2 Global Tumor Immunotherapy Forecasted Market Size by Application (2023-2028)

6 North America

6.1 North America Tumor Immunotherapy Market Size (2017-2028)

6.2 North America Tumor Immunotherapy Market Size by Type

6.2.1 North America Tumor Immunotherapy Market Size by Type (2017-2022)

6.2.2 North America Tumor Immunotherapy Market Size by Type (2023-2028)

6.2.3 North America Tumor Immunotherapy Market Share by Type (2017-2028)

6.3 North America Tumor Immunotherapy Market Size by Application

6.3.1 North America Tumor Immunotherapy Market Size by Application (2017-2022)

6.3.2 North America Tumor Immunotherapy Market Size by Application (2023-2028)

6.3.3 North America Tumor Immunotherapy Market Share by Application (2017-2028)

6.4 North America Tumor Immunotherapy Market Size by Country

6.4.1 North America Tumor Immunotherapy Market Size by Country (2017-2022)

6.4.2 North America Tumor Immunotherapy Market Size by Country (2023-2028)

6.4.3 United States

6.4.4 Canada

7 Europe

7.1 Europe Tumor Immunotherapy Market Size (2017-2028)

7.2 Europe Tumor Immunotherapy Market Size by Type

7.2.1 Europe Tumor Immunotherapy Market Size by Type (2017-2022)

7.2.2 Europe Tumor Immunotherapy Market Size by Type (2023-2028)

7.2.3 Europe Tumor Immunotherapy Market Share by Type (2017-2028)

7.3 Europe Tumor Immunotherapy Market Size by Application

7.3.1 Europe Tumor Immunotherapy Market Size by Application (2017-2022)

7.3.2 Europe Tumor Immunotherapy Market Size by Application (2023-2028)

7.3.3 Europe Tumor Immunotherapy Market Share by Application (2017-2028)

7.4 Europe Tumor Immunotherapy Market Size by Country

7.4.1 Europe Tumor Immunotherapy Market Size by Country (2017-2022)

7.4.2 Europe Tumor Immunotherapy Market Size by Country (2023-2028)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Tumor Immunotherapy Market Size (2017-2028)

8.2 Asia-Pacific Tumor Immunotherapy Market Size by Type

8.2.1 Asia-Pacific Tumor Immunotherapy Market Size by Type (2017-2022)

8.2.2 Asia-Pacific Tumor Immunotherapy Market Size by Type (2023-2028)

8.2.3 Asia-Pacific Tumor Immunotherapy Market Share by Type (2017-2028)

8.3 Asia-Pacific Tumor Immunotherapy Market Size by Application

8.3.1 Asia-Pacific Tumor Immunotherapy Market Size by Application (2017-2022)

8.3.2 Asia-Pacific Tumor Immunotherapy Market Size by Application (2023-2028)

8.3.3 Asia-Pacific Tumor Immunotherapy Market Share by Application (2017-2028)

8.4 Asia-Pacific Tumor Immunotherapy Market Size by Region

8.4.1 Asia-Pacific Tumor Immunotherapy Market Size by Region (2017-2022)

8.4.2 Asia-Pacific Tumor Immunotherapy Market Size by Region (2023-2028)

8.4.3 China

8.4.4 Japan

8.4.5 South Korea

8.4.6 Southeast Asia

8.4.7 India

8.4.8 Australia

9 Latin America

9.1 Latin America Tumor Immunotherapy Market Size (2017-2028)

9.2 Latin America Tumor Immunotherapy Market Size by Type

9.2.1 Latin America Tumor Immunotherapy Market Size by Type (2017-2022)

9.2.2 Latin America Tumor Immunotherapy Market Size by Type (2023-2028)

9.2.3 Latin America Tumor Immunotherapy Market Share by Type (2017-2028)

9.3 Latin America Tumor Immunotherapy Market Size by Application

9.3.1 Latin America Tumor Immunotherapy Market Size by Application (2017-2022)

9.3.2 Latin America Tumor Immunotherapy Market Size by Application (2023-2028)

9.3.3 Latin America Tumor Immunotherapy Market Share by Application (2017-2028)

9.4 Latin America Tumor Immunotherapy Market Size by Country

9.4.1 Latin America Tumor Immunotherapy Market Size by Country (2017-2022)

9.4.2 Latin America Tumor Immunotherapy Market Size by Country (2023-2028)

9.4.3 Mexico

9.4.4 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Tumor Immunotherapy Market Size (2017-2028)

10.2 Middle East & Africa Tumor Immunotherapy Market Size by Type

10.2.1 Middle East & Africa Tumor Immunotherapy Market Size by Type (2017-2022)

10.2.2 Middle East & Africa Tumor Immunotherapy Market Size by Type (2023-2028)

10.2.3 Middle East & Africa Tumor Immunotherapy Market Share by Type (2017-2028)

10.3 Middle East & Africa Tumor Immunotherapy Market Size by Application

10.3.1 Middle East & Africa Tumor Immunotherapy Market Size by Application (2017-2022)

10.3.2 Middle East & Africa Tumor Immunotherapy Market Size by Application (2023-2028)

10.3.3 Middle East & Africa Tumor Immunotherapy Market Share by Application (2017-2028)

10.4 Middle East & Africa Tumor Immunotherapy Market Size by Country

10.4.1 Middle East & Africa Tumor Immunotherapy Market Size by Country (2017-2022)

10.4.2 Middle East & Africa Tumor Immunotherapy Market Size by Country (2023-2028)

10.4.3 Turkey

10.4.4 Saudi Arabia

10.4.5 UAE

11 Key Players Profiles

11.1 Roche

11.1.1 Roche Company Details

11.1.2 Roche Business Overview

11.1.3 Roche Tumor Immunotherapy Introduction

11.1.4 Roche Revenue in Tumor Immunotherapy Business (2017-2022)

11.1.5 Roche Recent Developments

11.2 Merck

11.2.1 Merck Company Details

11.2.2 Merck Business Overview

11.2.3 Merck Tumor Immunotherapy Introduction

11.2.4 Merck Revenue in Tumor Immunotherapy Business (2017-2022)

11.2.5 Merck Recent Developments

11.3 Novartis

11.3.1 Novartis Company Details

11.3.2 Novartis Business Overview

11.3.3 Novartis Tumor Immunotherapy Introduction

11.3.4 Novartis Revenue in Tumor Immunotherapy Business (2017-2022)

11.3.5 Novartis Recent Developments

11.4 Johnson & Johnson

11.4.1 Johnson & Johnson Company Details

11.4.2 Johnson & Johnson Business Overview

11.4.3 Johnson & Johnson Tumor Immunotherapy Introduction

11.4.4 Johnson & Johnson Revenue in Tumor Immunotherapy Business (2017-2022)

11.4.5 Johnson & Johnson Recent Developments

11.5 GlaxoSmithKline

11.5.1 GlaxoSmithKline Company Details

11.5.2 GlaxoSmithKline Business Overview

11.5.3 GlaxoSmithKline Tumor Immunotherapy Introduction

11.5.4 GlaxoSmithKline Revenue in Tumor Immunotherapy Business (2017-2022)

11.5.5 GlaxoSmithKline Recent Developments

11.6 AbbVie

11.6.1 AbbVie Company Details

11.6.2 AbbVie Business Overview

11.6.3 AbbVie Tumor Immunotherapy Introduction

11.6.4 AbbVie Revenue in Tumor Immunotherapy Business (2017-2022)

11.6.5 AbbVie Recent Developments

11.7 ELI Lilly

11.7.1 ELI Lilly Company Details

11.7.2 ELI Lilly Business Overview

11.7.3 ELI Lilly Tumor Immunotherapy Introduction

11.7.4 ELI Lilly Revenue in Tumor Immunotherapy Business (2017-2022)

11.7.5 ELI Lilly Recent Developments

11.8 Amgen

11.8.1 Amgen Company Details

11.8.2 Amgen Business Overview

11.8.3 Amgen Tumor Immunotherapy Introduction

11.8.4 Amgen Revenue in Tumor Immunotherapy Business (2017-2022)

11.8.5 Amgen Recent Developments

11.9 AstraZeneca

11.9.1 AstraZeneca Company Details

11.9.2 AstraZeneca Business Overview

11.9.3 AstraZeneca Tumor Immunotherapy Introduction

11.9.4 AstraZeneca Revenue in Tumor Immunotherapy Business (2017-2022)

11.9.5 AstraZeneca Recent Developments

11.10 Bristol-Mysers Squibb

11.10.1 Bristol-Mysers Squibb Company Details

11.10.2 Bristol-Mysers Squibb Business Overview

11.10.3 Bristol-Mysers Squibb Tumor Immunotherapy Introduction

11.10.4 Bristol-Mysers Squibb Revenue in Tumor Immunotherapy Business (2017-2022)

11.10.5 Bristol-Mysers Squibb Recent Developments

11.11 Kite Pharma

11.11.1 Kite Pharma Company Details

11.11.2 Kite Pharma Business Overview

11.11.3 Kite Pharma Tumor Immunotherapy Introduction

11.11.4 Kite Pharma Revenue in Tumor Immunotherapy Business (2017-2022)

11.11.5 Kite Pharma Recent Developments

11.12 Adaptimmune

11.12.1 Adaptimmune Company Details

11.12.2 Adaptimmune Business Overview

11.12.3 Adaptimmune Tumor Immunotherapy Introduction

11.12.4 Adaptimmune Revenue in Tumor Immunotherapy Business (2017-2022)

11.12.5 Adaptimmune Recent Developments

11.13 Altor Bioscience Corporation

11.13.1 Altor Bioscience Corporation Company Details

11.13.2 Altor Bioscience Corporation Business Overview

11.13.3 Altor Bioscience Corporation Tumor Immunotherapy Introduction

11.13.4 Altor Bioscience Corporation Revenue in Tumor Immunotherapy Business (2017-2022)

11.13.5 Altor Bioscience Corporation Recent Developments

11.14 Cellectis

11.14.1 Cellectis Company Details

11.14.2 Cellectis Business Overview

11.14.3 Cellectis Tumor Immunotherapy Introduction

11.14.4 Cellectis Revenue in Tumor Immunotherapy Business (2017-2022)

11.14.5 Cellectis Recent Developments

11.15 Juno Therapeutics

11.15.1 Juno Therapeutics Company Details

11.15.2 Juno Therapeutics Business Overview

11.15.3 Juno Therapeutics Tumor Immunotherapy Introduction

11.15.4 Juno Therapeutics Revenue in Tumor Immunotherapy Business (2017-2022)

11.15.5 Juno Therapeutics Recent Developments

11.16 Takara Bio

11.16.1 Takara Bio Company Details

11.16.2 Takara Bio Business Overview

11.16.3 Takara Bio Tumor Immunotherapy Introduction

11.16.4 Takara Bio Revenue in Tumor Immunotherapy Business (2017-2022)

11.16.5 Takara Bio Recent Developments

11.17 Unum Therapeutics

11.17.1 Unum Therapeutics Company Details

11.17.2 Unum Therapeutics Business Overview

11.17.3 Unum Therapeutics Tumor Immunotherapy Introduction

11.17.4 Unum Therapeutics Revenue in Tumor Immunotherapy Business (2017-2022)

11.17.5 Unum Therapeutics Recent Developments

11.18 Sunway

11.18.1 Sunway Company Details

11.18.2 Sunway Business Overview

11.18.3 Sunway Tumor Immunotherapy Introduction

11.18.4 Sunway Revenue in Tumor Immunotherapy Business (2017-2022)

11.18.5 Sunway Recent Developments

11.19 Junshi Bio

11.19.1 Junshi Bio Company Details

11.19.2 Junshi Bio Business Overview

11.19.3 Junshi Bio Tumor Immunotherapy Introduction

11.19.4 Junshi Bio Revenue in Tumor Immunotherapy Business (2017-2022)

11.19.5 Junshi Bio Recent Developments

11.20 Cinda Bio

11.20.1 Cinda Bio Company Details

11.20.2 Cinda Bio Business Overview

11.20.3 Cinda Bio Tumor Immunotherapy Introduction

11.20.4 Cinda Bio Revenue in Tumor Immunotherapy Business (2017-2022)

11.20.5 Cinda Bio Recent Developments

11.21 BeiGene

11.21.1 BeiGene Company Details

11.21.2 BeiGene Business Overview

11.21.3 BeiGene Tumor Immunotherapy Introduction

11.21.4 BeiGene Revenue in Tumor Immunotherapy Business (2017-2022)

11.21.5 BeiGene Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Author Details

13.3 Disclaimer

List of Tables

Table 1. Global Tumor Immunotherapy Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028

Table 2. Key Players of Tumor Infiltrating Lymphocyte (TIL) Treatment

Table 3. Key Players of Engineered T Cell Receptor (TCR) Therapy

Table 4. Key Players of Chimeric Antigen Receptor (CAR) T Cell Therapy

Table 5. Key Players of Natural Killer (NK) Cell Therapy

Table 6. Key Players of Other

Table 7. Global Tumor Immunotherapy Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028

Table 8. Global Tumor Immunotherapy Market Size by Region (US$ Million): 2017 VS 2021 VS 2028

Table 9. Global Tumor Immunotherapy Market Size by Region (2017-2022) & (US$ Million)

Table 10. Global Tumor Immunotherapy Market Share by Region (2017-2022)

Table 11. Global Tumor Immunotherapy Forecasted Market Size by Region (2023-2028) & (US$ Million)

Table 12. Global Tumor Immunotherapy Market Share by Region (2023-2028)

Table 13. Tumor Immunotherapy Market Trends

Table 14. Tumor Immunotherapy Market Drivers

Table 15. Tumor Immunotherapy Market Challenges

Table 16. Tumor Immunotherapy Market Restraints

Table 17. Global Tumor Immunotherapy Revenue by Players (2017-2022) & (US$ Million)

Table 18. Global Tumor Immunotherapy Revenue Share by Players (2017-2022)

Table 19. Global Top Tumor Immunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunotherapy as of 2021)

Table 20. Ranking of Global Top Tumor Immunotherapy Companies by Revenue (US$ Million) in 2021

Table 21. Global 5 Largest Players Market Share by Tumor Immunotherapy Revenue (CR5 and HHI) & (2017-2022)

Table 22. Key Players Headquarters and Area Served

Table 23. Key Players Tumor Immunotherapy Product Solution and Service

Table 24. Date of Enter into Tumor Immunotherapy Market

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Tumor Immunotherapy Market Size by Type (2017-2022) & (US$ Million)

Table 27. Global Tumor Immunotherapy Revenue Market Share by Type (2017-2022)

Table 28. Global Tumor Immunotherapy Forecasted Market Size by Type (2023-2028) & (US$ Million)

Table 29. Global Tumor Immunotherapy Revenue Market Share by Type (2023-2028)

Table 30. Global Tumor Immunotherapy Market Size by Application (2017-2022) & (US$ Million)

Table 31. Global Tumor Immunotherapy Revenue Share by Application (2017-2022)

Table 32. Global Tumor Immunotherapy Forecasted Market Size by Application (2023-2028) & (US$ Million)

Table 33. Global Tumor Immunotherapy Revenue Share by Application (2023-2028)

Table 34. North America Tumor Immunotherapy Market Size by Type (2017-2022) & (US$ Million)

Table 35. North America Tumor Immunotherapy Market Size by Type (2023-2028) & (US$ Million)

Table 36. North America Tumor Immunotherapy Market Size by Application (2017-2022) & (US$ Million)

Table 37. North America Tumor Immunotherapy Market Size by Application (2023-2028) & (US$ Million)

Table 38. North America Tumor Immunotherapy Market Size by Country (2017-2022) & (US$ Million)

Table 39. North America Tumor Immunotherapy Market Size by Country (2023-2028) & (US$ Million)

Table 40. Europe Tumor Immunotherapy Market Size by Type (2017-2022) & (US$ Million)

Table 41. Europe Tumor Immunotherapy Market Size by Type (2023-2028) & (US$ Million)

Table 42. Europe Tumor Immunotherapy Market Size by Application (2017-2022) & (US$ Million)

Table 43. Europe Tumor Immunotherapy Market Size by Application (2023-2028) & (US$ Million)

Table 44. Europe Tumor Immunotherapy Market Size by Country (2017-2022) & (US$ Million)

Table 45. Europe Tumor Immunotherapy Market Size by Country (2023-2028) & (US$ Million)

Table 46. Asia Pacific Tumor Immunotherapy Market Size by Type (2017-2022) & (US$ Million)

Table 47. Asia Pacific Tumor Immunotherapy Market Size by Type (2023-2028) & (US$ Million)

Table 48. Asia Pacific Tumor Immunotherapy Market Size by Application (2017-2022) & (US$ Million)

Table 49. Asia Pacific Tumor Immunotherapy Market Size by Application (2023-2028) & (US$ Million)

Table 50. Asia Pacific Tumor Immunotherapy Market Size by Region (2017-2022) & (US$ Million)

Table 51. Asia Pacific Tumor Immunotherapy Market Size by Region (2023-2028) & (US$ Million)

Table 52. Latin America Tumor Immunotherapy Market Size by Type (2017-2022) & (US$ Million)

Table 53. Latin America Tumor Immunotherapy Market Size by Type (2023-2028) & (US$ Million)

Table 54. Latin America Tumor Immunotherapy Market Size by Application (2017-2022) & (US$ Million)

Table 55. Latin America Tumor Immunotherapy Market Size by Application (2023-2028) & (US$ Million)

Table 56. Latin America Tumor Immunotherapy Market Size by Country (2017-2022) & (US$ Million)

Table 57. Latin America Tumor Immunotherapy Market Size by Country (2023-2028) & (US$ Million)

Table 58. Middle East and Africa Tumor Immunotherapy Market Size by Type (2017-2022) & (US$ Million)

Table 59. Middle East and Africa Tumor Immunotherapy Market Size by Type (2023-2028) & (US$ Million)

Table 60. Middle East and Africa Tumor Immunotherapy Market Size by Application (2017-2022) & (US$ Million)

Table 61. Middle East and Africa Tumor Immunotherapy Market Size by Application (2023-2028) & (US$ Million)

Table 62. Middle East and Africa Tumor Immunotherapy Market Size by Country (2017-2022) & (US$ Million)

Table 63. Middle East and Africa Tumor Immunotherapy Market Size by Country (2023-2028) & (US$ Million)

Table 64. Roche Company Details

Table 65. Roche Business Overview

Table 66. Roche Tumor Immunotherapy Product

Table 67. Roche Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)

Table 68. Roche Recent Developments

Table 69. Merck Company Details

Table 70. Merck Business Overview

Table 71. Merck Tumor Immunotherapy Product

Table 72. Merck Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)

Table 73. Merck Recent Developments

Table 74. Novartis Company Details

Table 75. Novartis Business Overview

Table 76. Novartis Tumor Immunotherapy Product

Table 77. Novartis Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)

Table 78. Novartis Recent Developments

Table 79. Johnson & Johnson Company Details

Table 80. Johnson & Johnson Business Overview

Table 81. Johnson & Johnson Tumor Immunotherapy Product

Table 82. Johnson & Johnson Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)

Table 83. Johnson & Johnson Recent Developments

Table 84. GlaxoSmithKline Company Details

Table 85. GlaxoSmithKline Business Overview

Table 86. GlaxoSmithKline Tumor Immunotherapy Product

Table 87. GlaxoSmithKline Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)

Table 88. GlaxoSmithKline Recent Developments

Table 89. AbbVie Company Details

Table 90. AbbVie Business Overview

Table 91. AbbVie Tumor Immunotherapy Product

Table 92. AbbVie Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)

Table 93. AbbVie Recent Developments

Table 94. ELI Lilly Company Details

Table 95. ELI Lilly Business Overview

Table 96. ELI Lilly Tumor Immunotherapy Product

Table 97. ELI Lilly Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)

Table 98. ELI Lilly Recent Developments

Table 99. Amgen Company Details

Table 100. Amgen Business Overview

Table 101. Amgen Tumor Immunotherapy Product

Table 102. Amgen Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)

Table 103. Amgen Recent Developments

Table 104. AstraZeneca Company Details

Table 105. AstraZeneca Business Overview

Table 106. AstraZeneca Tumor Immunotherapy Product

Table 107. AstraZeneca Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)

Table 108. AstraZeneca Recent Developments

Table 109. Bristol-Mysers Squibb Company Details

Table 110. Bristol-Mysers Squibb Business Overview

Table 111. Bristol-Mysers Squibb Tumor Immunotherapy Product

Table 112. Bristol-Mysers Squibb Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)

Table 113. Bristol-Mysers Squibb Recent Developments

Table 114. Kite Pharma Company Details

Table 115. Kite Pharma Business Overview

Table 116. Kite Pharma Tumor Immunotherapy Product

Table 117. Kite Pharma Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)

Table 118. Kite Pharma Recent Developments

Table 119. Adaptimmune Company Details

Table 120. Adaptimmune Business Overview

Table 121. Adaptimmune Tumor Immunotherapy Product

Table 122. Adaptimmune Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)

Table 123. Adaptimmune Recent Developments

Table 124. Altor Bioscience Corporation Company Details

Table 125. Altor Bioscience Corporation Business Overview

Table 126. Altor Bioscience Corporation Tumor Immunotherapy Product

Table 127. Altor Bioscience Corporation Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)

Table 128. Altor Bioscience Corporation Recent Developments

Table 129. Cellectis Company Details

Table 130. Cellectis Business Overview

Table 131. Cellectis Tumor Immunotherapy Product

Table 132. Cellectis Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)

Table 133. Cellectis Recent Developments

Table 134. Juno Therapeutics Company Details

Table 135. Juno Therapeutics Business Overview

Table 136. Juno Therapeutics Tumor Immunotherapy Product

Table 137. Juno Therapeutics Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)

Table 138. Juno Therapeutics Recent Developments

Table 139. Takara Bio Company Details

Table 140. Takara Bio Business Overview

Table 141. Takara Bio Tumor Immunotherapy Product

Table 142. Takara Bio Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)

Table 143. Takara Bio Recent Developments

Table 144. Unum Therapeutics Company Details

Table 145. Unum Therapeutics Business Overview

Table 146. Unum Therapeutics Tumor Immunotherapy Product

Table 147. Unum Therapeutics Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)

Table 148. Unum Therapeutics Recent Developments

Table 149. Sunway Company Details

Table 150. Sunway Business Overview

Table 151. Sunway Tumor Immunotherapy Product

Table 152. Sunway Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)

Table 153. Sunway Recent Developments

Table 154. Junshi Bio Company Details

Table 155. Junshi Bio Business Overview

Table 156. Junshi Bio Tumor Immunotherapy Product

Table 157. Junshi Bio Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)

Table 158. Junshi Bio Recent Developments

Table 159. Cinda Bio Company Details

Table 160. Cinda Bio Business Overview

Table 161. Cinda Bio Tumor Immunotherapy Product

Table 162. Cinda Bio Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)

Table 163. Cinda Bio Recent Developments

Table 164. BeiGene Company Details

Table 165. BeiGene Business Overview

Table 166. BeiGene Tumor Immunotherapy Product

Table 167. BeiGene Revenue in Tumor Immunotherapy Business (2017-2022) & (US$ Million)

Table 168. BeiGene Recent Developments

Table 169. Research Programs/Design for This Report

Table 170. Key Data Information from Secondary Sources

Table 171. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Tumor Immunotherapy Market Share by Type: 2021 VS 2028

Figure 2. Tumor Infiltrating Lymphocyte (TIL) Treatment Features

Figure 3. Engineered T Cell Receptor (TCR) Therapy Features

Figure 4. Chimeric Antigen Receptor (CAR) T Cell Therapy Features

Figure 5. Natural Killer (NK) Cell Therapy Features

Figure 6. Other Features

Figure 7. Global Tumor Immunotherapy Market Share by Application: 2021 VS 2028

Figure 8. Biopharmaceutical Company Case Studies

Figure 9. Hospital Case Studies

Figure 10. Universities And Other Scientific Research Institutions Case Studies

Figure 11. Other Case Studies

Figure 12. Tumor Immunotherapy Report Years Considered

Figure 13. Global Tumor Immunotherapy Market Size (US$ Million), Year-over-Year: 2017-2028

Figure 14. Global Tumor Immunotherapy Market Size, (US$ Million), 2017 VS 2021 VS 2028

Figure 15. Global Tumor Immunotherapy Market Share by Region: 2021 VS 2028

Figure 16. Global Tumor Immunotherapy Market Share by Players in 2021

Figure 17. Global Top Tumor Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunotherapy as of 2021)

Figure 18. The Top 10 and 5 Players Market Share by Tumor Immunotherapy Revenue in 2021

Figure 19. North America Tumor Immunotherapy Market Size YoY (2017-2028) & (US$ Million)

Figure 20. North America Tumor Immunotherapy Market Size Market Share by Type (2017-2028)

Figure 21. North America Tumor Immunotherapy Market Size Market Share by Application (2017-2028)

Figure 22. North America Tumor Immunotherapy Market Size Share by Country (2017-2028)

Figure 23. United States Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 24. Canada Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 25. Europe Tumor Immunotherapy Market Size YoY (2017-2028) & (US$ Million)

Figure 26. Europe Tumor Immunotherapy Market Size Market Share by Type (2017-2028)

Figure 27. Europe Tumor Immunotherapy Market Size Market Share by Application (2017-2028)

Figure 28. Europe Tumor Immunotherapy Market Size Share by Country (2017-2028)

Figure 29. Germany Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 30. France Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 31. U.K. Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 32. Italy Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 33. Russia Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 34. Nordic Countries Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 35. Asia-Pacific Tumor Immunotherapy Market Size YoY (2017-2028) & (US$ Million)

Figure 36. Asia Pacific Tumor Immunotherapy Market Size Market Share by Type (2017-2028)

Figure 37. Asia Pacific Tumor Immunotherapy Market Size Market Share by Application (2017-2028)

Figure 38. Asia Pacific Tumor Immunotherapy Market Size Share by Region (2017-2028)

Figure 39. China Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 40. Japan Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 41. South Korea Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 42. Southeast Asia Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 43. India Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 44. Australia Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

List of Figures

Figure 45. Latin America Tumor Immunotherapy Market Size YoY (2017-2028) & (US$ Million)

Figure 46. Latin America Tumor Immunotherapy Market Size Market Share by Type (2017-2028)

Figure 47. Latin America Tumor Immunotherapy Market Size Market Share by Application (2017-2028)

Figure 48. Latin America Tumor Immunotherapy Market Size Share by Country (2017-2028)

Figure 49. Mexico Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 50. Brazil Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 51. Middle East & Africa Tumor Immunotherapy Market Size YoY (2017-2028) & (US$ Million)

Figure 52. Middle East and Africa Tumor Immunotherapy Market Size Market Share by Type (2017-2028)

Figure 53. Middle East and Africa Tumor Immunotherapy Market Size Market Share by Application (2017-2028)

Figure 54. Middle East and Africa Tumor Immunotherapy Market Size Share by Country (2017-2028)

Figure 55. Turkey Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 56. Saudi Arabia Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 57. UAE Tumor Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)

Figure 58. Roche Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)

Figure 59. Merck Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)

Figure 60. Novartis Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)

Figure 61. Johnson & Johnson Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)

Figure 62. GlaxoSmithKline Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)

Figure 63. AbbVie Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)

Figure 64. ELI Lilly Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)

Figure 65. Amgen Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)

Figure 66. AstraZeneca Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)

Figure 67. Bristol-Mysers Squibb Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)

Figure 68. Kite Pharma Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)

Figure 69. Adaptimmune Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)

Figure 70. Altor Bioscience Corporation Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)

Figure 71. Cellectis Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)

Figure 72. Juno Therapeutics Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)

Figure 73. Takara Bio Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)

Figure 74. Unum Therapeutics Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)

Figure 75. Sunway Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)

Figure 76. Junshi Bio Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)

Figure 77. Cinda Bio Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)

Figure 78. BeiGene Revenue Growth Rate in Tumor Immunotherapy Business (2017-2022)

Figure 79. Bottom-up and Top-down Approaches for This Report

Figure 80. Data Triangulation

Figure 81. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Tumor Immunotherapy Market Insights and Forecast to 2028

Published Date: April 2022

Report Code: QYRE-Auto-18E7950

Tumor Immunotherapy Market Insights and Forecast to 2028

FEATURED COMPANIES

Tumor Immunotherapy Market Outlook - 2028

Tumor Immunotherapy Market Size and Share

Segment By Type

Segment By Application

By Company

By Region

FEATURED COMPANIES

RELATED REPORTS